Compare BBCP & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | GLSI |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 372.0M |
| IPO Year | 2017 | 2020 |
| Metric | BBCP | GLSI |
|---|---|---|
| Price | $7.15 | $25.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.25 | ★ $50.00 |
| AVG Volume (30 Days) | 101.4K | ★ 150.2K |
| Earning Date | 03-10-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $0.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.04 | $7.78 |
| 52 Week High | $7.80 | $34.10 |
| Indicator | BBCP | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 47.90 |
| Support Level | $6.64 | $21.43 |
| Resistance Level | $7.28 | $29.91 |
| Average True Range (ATR) | 0.32 | 2.25 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 76.73 | 35.48 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.